On Friday, CEO Dawn Svoronos bought 50,500 shares of her own company in the open market. She paid between $0.27 and $0.28 for the shares.
She was joined, a day earlier, by company insider Gérald Lacoste, who bought 40,000 shares at $0.27 and $0.275.
Theratechnologies’ management is no doubt hoping 2013 will be an improvement over a 2012 that was difficult for its investors. Shares of the company fell in half last June when Ferrer announced it would withdraw the marketing authorization application with the European Medicines Agency for Egrifta, the company’s tesamorelin application proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Byron Capital healthcare analyst Douglas Loe thinks Theratechnologies will trade sideways until its regulatory status, which has been a persistent theme with the company, is resolved in Latin America and in Europe.
At press time, shares of Theratechnologies on the TSX were even at $0.285.
The so-called "Big Beautiful Bill" may not be beautiful for some, but it might not be the worst thing for… [Read More]
Following the company's second quarter results, Beacon Securities analyst Russell Stanley has raised his price target on Firan Technology Group… [Read More]
Following an update on its Canadian clinics business, Raymond James analyst Michael W. Freeman remains bullish on WELL Health Technologies… [Read More]
Following a sizeable acquisition, Paradigm Capital analyst Daniel Rosenberg has raised his price target on VitalHub (VitalHub Stock Quote, Chart,… [Read More]
Following a recent contract win, Ventum Capital markets analyst Rob Goff has raised his price target on Volatus Aerospace (Volatus… [Read More]
Canada’s labour market has softened sharply since the start of the year, with the unemployment rate reaching 7% in May,… [Read More]